AU2003256079A8 - Method for treating synovial sarcoma - Google Patents

Method for treating synovial sarcoma

Info

Publication number
AU2003256079A8
AU2003256079A8 AU2003256079A AU2003256079A AU2003256079A8 AU 2003256079 A8 AU2003256079 A8 AU 2003256079A8 AU 2003256079 A AU2003256079 A AU 2003256079A AU 2003256079 A AU2003256079 A AU 2003256079A AU 2003256079 A8 AU2003256079 A8 AU 2003256079A8
Authority
AU
Australia
Prior art keywords
synovial sarcoma
treating synovial
treating
sarcoma
synovial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003256079A
Other versions
AU2003256079A1 (en
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JAPAN GOVERNMENT
Oncotherapy Science Inc
University of Tokyo NUC
Original Assignee
JAPAN GOVERNMENT
Oncotherapy Science Inc
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JAPAN GOVERNMENT, Oncotherapy Science Inc, University of Tokyo NUC filed Critical JAPAN GOVERNMENT
Publication of AU2003256079A8 publication Critical patent/AU2003256079A8/en
Publication of AU2003256079A1 publication Critical patent/AU2003256079A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2003256079A 2002-08-30 2003-08-21 Method for treating synovial sarcoma Abandoned AU2003256079A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40750602P 2002-08-30 2002-08-30
US60/407,506 2002-08-30
US48619503P 2003-07-11 2003-07-11
US60/486,195 2003-07-11
PCT/JP2003/010591 WO2004020668A2 (en) 2002-08-30 2003-08-21 Method for treating synovial sarcoma

Publications (2)

Publication Number Publication Date
AU2003256079A8 true AU2003256079A8 (en) 2004-03-19
AU2003256079A1 AU2003256079A1 (en) 2004-03-19

Family

ID=31981517

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003256079A Abandoned AU2003256079A1 (en) 2002-08-30 2003-08-21 Method for treating synovial sarcoma

Country Status (2)

Country Link
AU (1) AU2003256079A1 (en)
WO (1) WO2004020668A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803370B2 (en) 2002-08-30 2010-09-28 Oncotherapy Science, Inc. Method for treating synovial sarcoma
JP2008509076A (en) * 2004-08-05 2008-03-27 国立大学法人 東京大学 Method for treating synovial sarcoma using siRNA against FZD10
DE102004050620A1 (en) 2004-10-13 2006-04-20 Eberhard-Karls-Universität Tübingen Monoclonal antibody against Frizzled receptors
DK2500360T3 (en) 2005-10-31 2015-10-26 Oncomed Pharm Inc Compositions and methods for the diagnosis and treatment of cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US8221751B2 (en) 2006-06-21 2012-07-17 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to FZD10 and uses thereof
KR20090080082A (en) * 2006-11-14 2009-07-23 노파르티스 아게 Methods of treating, diagnosing or detecting cancer
CN105079805A (en) 2008-09-26 2015-11-25 昂考梅德药品有限公司 Frizzled-binding agents and uses thereof
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
EP2552953B1 (en) 2010-04-01 2017-05-17 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP3281640A1 (en) 2011-06-17 2018-02-14 President and Fellows of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
JP2016510411A (en) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods and monitoring of treatment with WNT pathway inhibitors
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TWI762516B (en) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 Monoclonal antibodies against FZD10 and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414580D0 (en) * 1994-07-19 1994-09-07 Cancer Res Campaign Tech Materials and methods relating to the diagnosis of synovial sarcomas
AU2001251034A1 (en) * 2000-03-31 2001-10-15 Gene Logic, Inc Gene expression profiles in esophageal tissue
JP2004522414A (en) * 2000-08-19 2004-07-29 アクソーディア・リミテッド Stem cell differentiation
CA2433742A1 (en) * 2001-01-11 2002-07-18 Curagen Corporation Proteins and nucleic acids encoding same
CA2444691A1 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US20030044409A1 (en) * 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
WO2003004045A2 (en) * 2001-07-05 2003-01-16 Xenon Genetics, Inc. Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors

Also Published As

Publication number Publication date
AU2003256079A1 (en) 2004-03-19
WO2004020668A3 (en) 2004-06-17
WO2004020668A2 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
IL164352A0 (en) Methods for treating tweak-related conditions
HK1074778A1 (en) Method for treating obesity
AU2003238155A8 (en) Method for pattern inspection
AU2003272713A8 (en) A method for treating severe tinnitus
AU2003304722A1 (en) Method for treating waste-activated sludge using elecroporation
GB0510178D0 (en) Process for demineralising coal
AU2003256079A8 (en) Method for treating synovial sarcoma
GB0203306D0 (en) Method
EP1581234A4 (en) Methods for treating migraine
EP1497856A4 (en) Method for ashing
AU2003258070A8 (en) Electrodionization method
IL163835A0 (en) Method for treating carbonaceous materials
PL376932A1 (en) Method for treating slag
IL150501A0 (en) Method for wagering
KR20050117604A (en) Apparatus for masssge using high frequency
AU2003253813A8 (en) Method for colpoplasty
EP1599193A4 (en) Method for treating hypothyroidism
GB0210523D0 (en) Method and apparatus for de-watering articles
AU2003222468A1 (en) Apparatus for treating solid waste
GB0221559D0 (en) Scribing apparatus
AU2003251208A8 (en) Apparatus for treating strip-shaped parts
GB0217417D0 (en) Process for treating waste
IL147468A0 (en) Apparatus for treating bruxism
GB0304215D0 (en) Method for treating waste
PL374000A1 (en) Improved process for hydroxyazapirones

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase